Krystal Other Current Liab vs Accounts Payable Analysis

KRYS Stock  USD 196.91  0.39  0.20%   
Krystal Biotech financial indicator trend analysis is infinitely more than just investigating Krystal Biotech recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Krystal Biotech is a good investment. Please check the relationship between Krystal Biotech Other Current Liab and its Accounts Payable accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Krystal Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.
For more information on how to buy Krystal Stock please use our How to Invest in Krystal Biotech guide.

Other Current Liab vs Accounts Payable

Other Current Liab vs Accounts Payable Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Krystal Biotech Other Current Liab account and Accounts Payable. At this time, the significance of the direction appears to have strong relationship.
The correlation between Krystal Biotech's Other Current Liab and Accounts Payable is 0.6. Overlapping area represents the amount of variation of Other Current Liab that can explain the historical movement of Accounts Payable in the same time period over historical financial statements of Krystal Biotech, assuming nothing else is changed. The correlation between historical values of Krystal Biotech's Other Current Liab and Accounts Payable is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Current Liab of Krystal Biotech are associated (or correlated) with its Accounts Payable. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Accounts Payable has no effect on the direction of Other Current Liab i.e., Krystal Biotech's Other Current Liab and Accounts Payable go up and down completely randomly.

Correlation Coefficient

0.6
Relationship DirectionPositive 
Relationship StrengthSignificant

Other Current Liab

Accounts Payable

An accounting item on the balance sheet that represents Krystal Biotech obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Krystal Biotech are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.
Most indicators from Krystal Biotech's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Krystal Biotech current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Krystal Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.
For more information on how to buy Krystal Stock please use our How to Invest in Krystal Biotech guide.At this time, Krystal Biotech's Selling General Administrative is comparatively stable compared to the past year. Tax Provision is likely to gain to about 2.1 M in 2024, whereas Issuance Of Capital Stock is likely to drop slightly above 164 M in 2024.
 2021 2022 2023 2024 (projected)
Depreciation And Amortization2.8M4.1M5.0M5.3M
Interest Income197K5.2M22.6M23.8M

Krystal Biotech fundamental ratios Correlations

0.810.930.991.00.770.990.96-0.93-0.950.70.860.980.920.9-0.730.820.990.830.990.980.971.00.97-0.950.93
0.810.610.850.810.760.850.76-0.85-0.770.690.860.730.860.88-0.380.740.840.930.80.840.750.830.73-0.860.81
0.930.610.930.930.610.90.97-0.74-0.960.60.660.980.80.78-0.740.80.930.620.950.930.980.90.98-0.880.86
0.990.850.930.980.730.980.98-0.89-0.970.720.830.980.910.91-0.680.860.990.840.991.00.980.980.98-0.970.93
1.00.810.930.980.770.990.96-0.93-0.950.70.870.980.920.9-0.730.820.990.820.990.980.961.00.97-0.950.93
0.770.760.610.730.770.80.67-0.85-0.690.560.830.660.80.82-0.450.480.780.70.740.70.660.810.66-0.760.71
0.990.850.90.980.990.80.96-0.94-0.940.790.890.960.950.94-0.630.861.00.870.980.980.950.990.95-0.980.95
0.960.760.970.980.960.670.96-0.81-0.990.680.750.990.870.87-0.680.870.970.740.980.981.00.941.0-0.950.91
-0.93-0.85-0.74-0.89-0.93-0.85-0.94-0.810.8-0.72-0.97-0.85-0.92-0.910.6-0.73-0.92-0.91-0.9-0.88-0.81-0.95-0.810.89-0.89
-0.95-0.77-0.96-0.97-0.95-0.69-0.94-0.990.8-0.61-0.74-0.96-0.88-0.890.66-0.86-0.96-0.73-0.97-0.97-0.99-0.93-0.990.94-0.91
0.70.690.60.720.70.560.790.68-0.72-0.610.740.70.770.72-0.150.790.750.820.670.730.670.690.63-0.830.75
0.860.860.660.830.870.830.890.75-0.97-0.740.740.780.960.93-0.410.760.870.950.830.830.740.890.74-0.870.91
0.980.730.980.980.980.660.960.99-0.85-0.960.70.780.880.85-0.720.850.980.760.980.980.990.960.99-0.940.92
0.920.860.80.910.920.80.950.87-0.92-0.880.770.960.880.98-0.430.880.940.920.910.910.870.930.86-0.950.98
0.90.880.780.910.90.820.940.87-0.91-0.890.720.930.850.98-0.420.870.930.90.90.90.860.920.85-0.950.95
-0.73-0.38-0.74-0.68-0.73-0.45-0.63-0.680.60.66-0.15-0.41-0.72-0.43-0.42-0.32-0.66-0.33-0.73-0.67-0.69-0.72-0.730.51-0.48
0.820.740.80.860.820.480.860.87-0.73-0.860.790.760.850.880.87-0.320.860.820.850.880.870.80.84-0.910.92
0.990.840.930.990.990.781.00.97-0.92-0.960.750.870.980.940.93-0.660.860.850.990.990.970.990.97-0.980.94
0.830.930.620.840.820.70.870.74-0.91-0.730.820.950.760.920.9-0.330.820.850.80.840.740.840.72-0.880.88
0.990.80.950.990.990.740.980.98-0.9-0.970.670.830.980.910.9-0.730.850.990.80.990.980.990.98-0.950.93
0.980.840.931.00.980.70.980.98-0.88-0.970.730.830.980.910.9-0.670.880.990.840.990.980.970.98-0.970.94
0.970.750.980.980.960.660.951.0-0.81-0.990.670.740.990.870.86-0.690.870.970.740.980.980.941.0-0.940.91
1.00.830.90.981.00.810.990.94-0.95-0.930.690.890.960.930.92-0.720.80.990.840.990.970.940.95-0.950.93
0.970.730.980.980.970.660.951.0-0.81-0.990.630.740.990.860.85-0.730.840.970.720.980.981.00.95-0.930.9
-0.95-0.86-0.88-0.97-0.95-0.76-0.98-0.950.890.94-0.83-0.87-0.94-0.95-0.950.51-0.91-0.98-0.88-0.95-0.97-0.94-0.95-0.93-0.95
0.930.810.860.930.930.710.950.91-0.89-0.910.750.910.920.980.95-0.480.920.940.880.930.940.910.930.9-0.95
Click cells to compare fundamentals

Krystal Biotech Account Relationship Matchups

Krystal Biotech fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets209.0M310.8M626.3M558.5M818.4M859.3M
Other Current Liab19K(3.2M)16.2M21.7M26.0M27.3M
Total Current Liabilities3.3M15.5M25.7M28.8M33.1M34.7M
Total Stockholder Equity202.9M292.1M593.6M522.2M778.6M817.6M
Net Tangible Assets202.9M292.1M593.6M522.2M600.6M630.6M
Property Plant And Equipment Net11.2M34.2M119.6M169.7M168.2M176.6M
Net Debt(184.3M)(256.7M)(333.2M)(153.0M)(350.2M)(332.7M)
Retained Earnings(39.0M)(71.2M)(140.8M)(280.8M)(269.8M)(256.3M)
Accounts Payable724K2.1M8.4M4.0M1.8M2.5M
Cash187.5M268.3M341.2M161.9M358.3M202.5M
Non Current Assets Total13.1M35.8M184.0M174.7M230.4M242.0M
Non Currrent Assets Other1.5M1.6M74K324K263K249.9K
Cash And Short Term Investments193.7M271.3M438.1M379.2M532.2M271.9M
Common Stock Shares Outstanding15.9M18.8M22.2M25.5M27.8M18.0M
Liabilities And Stockholders Equity209.0M310.8M626.3M558.5M818.4M859.3M
Non Current Liabilities Total2.8M3.3M7.0M7.4M6.6M4.0M
Capital Surpluse133.2M242.0M363.3M734.5M844.7M886.9M
Other Current Assets2.2M7.6M8.3M4.6M6.7M4.2M
Other Stockholder Equity242.0M363.3M734.5M803.7M1.0B1.1B
Total Liab6.1M18.8M32.7M36.2M39.7M41.7M
Property Plant And Equipment Gross11.2M34.2M123.8M176.5M181.1M190.1M
Total Current Assets195.9M275.1M442.3M383.8M587.9M617.3M
Accumulated Other Comprehensive Income10K6K(163K)(728K)638K669.9K
Property Plant Equipment11.2M30.9M119.6M169.7M195.2M204.9M
Other Assets1.5M4.9M74K324K372.6K354.0K
Short Term Investments6.2M3.0M96.9M217.3M173.9M182.5M
Net Invested Capital202.9M292.1M593.6M522.2M778.6M401.1M
Net Working Capital192.6M259.6M416.5M354.9M554.8M304.5M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Krystal Stock Analysis

When running Krystal Biotech's price analysis, check to measure Krystal Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Krystal Biotech is operating at the current time. Most of Krystal Biotech's value examination focuses on studying past and present price action to predict the probability of Krystal Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Krystal Biotech's price. Additionally, you may evaluate how the addition of Krystal Biotech to your portfolios can decrease your overall portfolio volatility.